Amryt Pharma (AMYT)

Amryt Pharma is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

Rockfire Resources (ROCK)

the gold and base-metal focused explorer, announces that it has recently completed reprocessing of historical geophysical data from its 100%-owned Plateau Gold Deposit in Queensland, Australia.

Shanta Gold (SHG)

Shanta Gold is a producing gold company generating approximately US$100 million EBITDA pa (US$1900/oz). Shanta has three assets in two countries (Tanzania and Kenya) totalling 3.2 million ounces of gold grading 3.6 g/t contained.

Silence Therapeutics (SLN)

Silence Therapeutics is a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases.

SkinBioTherapeutics (SBTX)

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.

The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.

SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.